Document Detail

Antiischemic and hemodynamic effects of an oral single dose of 150 mg of the phosphodiesterase inhibitor enoximone in patients with coronary artery disease--relation to plasma concentration.
MedLine Citation:
PMID:  1832289     Owner:  NLM     Status:  MEDLINE    
The hemodynamic and antiischemic effects of a 150-mg single oral dose of the PDE inhibitor enoximone were correlated with the plasma levels of enoximone and its sulfoxide metabolite. Twenty-one patients with angiographically documented coronary artery disease were investigated by exercise testing 1 and 2 hours after drug administration. The control group consisted of 15 patients with proven coronary artery disease and stable reproducible angina pectoris on exercise. The enoximone group included 14 responders with therapeutic plasma concentrations 2 hours after drug intake and significantly reduced mean pulmonary artery pressures on exercise (from 42.4 +/- 8.6 to 30.9 +/- 11.2 mmHg, p less than 0.05). Compared to basal exercise values, responders showed a reduced ST-segment depression by 1 hour after drug intake (2.1 +/- 1.2 vs. 1.3 +/- 3 mm, p less than 0.05) and minimal values after 2 hours (0.9 +/- 1.0 mm, p less than 0.01) at comparable workloads. There were no significant changes in heart rate, blood pressure, cardiac output, and systemic vascular resistance. No significant improvement in the hemodynamic parameters and ST-segment depression was found in nonresponders with plasma concentrations below 100 ng/ml and 500 mg/ml for enoximone and its metabolite, respectively. In summary, oral administration of enoximone in patients with coronary artery disease led to favorable acute hemodynamic and antiischemic effects at sufficiently high plasma levels of enoximone and its sulfoxide metabolite.
V Mitrovic; O Petrovic; H Bahavar; J Neuzner; H A Dieterich; M Schlepper
Related Documents :
6428209 - Clinical studies with transdermal nitroglycerin.
1597219 - Predicting cardiac mortality after uncomplicated myocardial infarction by exercise radi...
7406059 - Ventricular recovery properties and qrst deflection area in cardiac electrograms.
3980219 - Deposition of excess amount of natural u from the atmosphere.
17497709 - Relative reinforcing value of exercise in inpatients with anorexia nervosa: model devel...
3086899 - Comparative clinical trial of isosorbide 5-mononitrate and sustained-release isosorbide...
17653139 - Endothelium-mediated modulation of ergoreflex and improvement in exercise ventilation b...
448449 - Selenium, vitamin e and the response to swimming stress in the rat.
25378959 - People who perceive themselves as active cannot identify the intensity recommended by t...
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy     Volume:  5     ISSN:  0920-3206     ISO Abbreviation:  Cardiovasc Drugs Ther     Publication Date:  1991 Aug 
Date Detail:
Created Date:  1991-10-15     Completed Date:  1991-10-15     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  8712220     Medline TA:  Cardiovasc Drugs Ther     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  689-95     Citation Subset:  IM    
Kerckhoff-Klinik of the Max-Planck Society, Bad Nauheim, FRG.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Administration, Oral
Cardiotonic Agents / administration & dosage*,  therapeutic use
Coronary Disease / drug therapy*
Electrocardiography / drug effects
Hemodynamics / drug effects*
Imidazoles / administration & dosage*,  blood,  therapeutic use
Middle Aged
Phosphodiesterase Inhibitors / administration & dosage*,  therapeutic use
Reg. No./Substance:
0/Cardiotonic Agents; 0/Imidazoles; 0/Phosphodiesterase Inhibitors; 77671-31-9/Enoximone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Steroid metabolism in gonads of turtle embryos as a function of the incubation temperature of eggs.
Next Document:  Accelerated myocardial metabolic and functional recovery with terminal nicorandil-Mg cardioplegia in...